Recent progress in biotechnology shows a clear move toward targeted cancer treatments and the development of oral medications for obesity management.

生物技術的近期進展顯示，目前明顯趨向於癌症標靶治療以及開發用於肥胖管理的口服藥物。

In the field of cancer research, new drugs called KRAS inhibitors, such as daraxonrasib, are showing positive results. Data shows that this drug can double the survival time for patients with advanced pancreatic cancer, increasing life expectancy to 13.2 months compared to 6.6 months with standard chemotherapy. Furthermore, combining vopimetostat and daraxonrasib has helped most patients achieve lasting results. Consequently, companies are investing heavily in this area, as seen when Johnson & Johnson bought Firefly Bio for $1 billion to improve its targeted therapy options.

在癌症研究領域，名為 KRAS 抑制劑的新藥（例如 daraxonrasib）正顯示出積極的結果。數據顯示，此藥物可將晚期胰臟癌患者的生存時間增加一倍，使預期壽命從標準化療的 6.6 個月增加至 13.2 個月。此外，將 vopimetostat 與 daraxonrasib 結合使用，已幫助大多數患者達到持久的效果。因此，企業正大量投資於此領域，例如強生 (Johnson & Johnson) 以 10 億美元收購 Firefly Bio，以改善其標靶治療選項。

At the same time, Novo Nordisk and Eli Lilly are competing strongly to lead the market for oral obesity pills. Novo Nordisk reported over 3 million prescriptions for its Wegovy pill, while Eli Lilly saw a large increase in the use of Foundayo. Both companies are preparing for new Medicare eligibility on July 1st; however, they have different strategies. Novo Nordisk emphasizes protection for the heart and kidneys, whereas Eli Lilly focuses on making the medication easier to take. Additionally, research into a drug called retatrutide shows a potential weight loss of 28%, although some patients experienced heart-related side effects.

與此同時，諾和諾德 (Novo Nordisk) 與禮來 (Eli Lilly) 正激烈競爭，以爭奪口服肥胖藥市場的領導地位。諾和諾德報告其 Wegovy 藥丸的處方量超過 300 萬份，而禮來則見到 Foundayo 的使用量大幅增加。兩家公司都在為 7 月 1 日起生效的新 Medicare 資格做準備；然而，它們的策略有所不同。諾和諾德強調心臟和腎臟的保護，而禮來則專注於提高藥物的服用便捷性。此外，對一種名為 retatrutide 藥物的研究顯示，體重潛在減輕幅度達 28%，儘管部分患者出現了心臟相關的副作用。

Other researchers are now focusing on the problems caused by rapid weight loss. For example, a drug called apitegromab helps patients keep more muscle mass when used with tirzepatide. Moreover, a large study of 161,000 patients suggests that GLP-1 users have a 41% lower risk of obesity-related cancers, though this benefit was not found in Black patients. Other industry news includes a partnership between Roche and Nurix Therapeutics and a business merger involving Treeline Biosciences and Standard BioTools.

其他研究人員目前正專注於快速減重引起的問題。例如，一種名為 apitegromab 的藥物在與 tirzepatide 合用時，能幫助患者保留更多肌肉量。此外，一項涉及 16.1 萬名患者的大型研究表明，GLP-1 使用者患肥胖相關癌症的風險降低了 41%，但此益處在黑人患者中未被發現。其他產業新聞包括羅氏 (Roche) 與 Nurix Therapeutics 的合作，以及 Treeline Biosciences 與 Standard BioTools 的企業合併。

The pharmaceutical industry is moving toward more effective targeted therapies and a wider variety of obesity treatments, although it still struggles to find ways to pay for expensive gene therapies.

製藥產業正趨向更有效的標靶治療以及更多樣化的肥胖症治療，儘管在如何支付昂貴的基因治療費用方面仍面臨困難。